

FOR IMMEDIATE RELEASE**HERITAGE INTRODUCES PROPOXYPHENE HCl CAPSULES**

Edison, New Jersey, June 29, 2009. Heritage Pharmaceuticals Inc. announced the immediate availability of Propoxyphene HCl Oral Capsules in 65 mg strength. Heritage received approval of its supplemental Abbreviated New Drug Application (ANDA) for its new manufacturing site qualification on March 23, 2009.

Propoxyphene Capsules are an AA Rated generic equivalent to Darvon[®] Capsules marketed by Xanodyne. Propoxyphene is a mild narcotic analgesic indicated for the relief of mild to moderate pain. Propoxyphene had U.S. brand and generic sales of approximately \$8 million for the 12-month period ending Dec. 31, 2008 according to IMS Health.

Heritage President & CEO, Jeffrey Glazer, stated, “The launch of Propoxyphene represents yet another successful manufacturing site qualification from our acquired product line. Heritage is pleased to introduce this high quality, niche product that is manufactured in the United States as we continue to build our pain management franchise. We look forward to additional product line growth as our pipeline matures through the regulatory process and we will continue to diligently execute our business plan toward becoming a premier generic pharmaceutical company providing affordable health care solutions to the U.S. consumer.”

About Heritage

Heritage Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic pharmaceutical products for the global prescription drug markets. Heritage launched its U.S. label in 2006 and currently markets 7 products over 30 SKU's, including Ethambutol tablets, Hydralazine tablets, Hydrochlorothiazide tablets, Sulindac tablets, Nimodipine soft gels, Propranolol tablets and Propoxyphene capsules. The Company's business model utilizes a virtually integrated global supply chain and resource network that leverages strategic outsourcing to U.S.F.D.A. approved manufacturing and development organizations in both North America and Asia. The Company owns a robust pipeline of multisource and high barrier products and will continue to introduce new generic products during 2009 following its tradition of premier quality, value and service in generics. www.heritagepharma.com

Contact:

Jeffrey Glazer, *President & CEO*
Jason Malek, *Director Sales Operations*
Heritage Pharmaceuticals Inc.
Toll free at: +1-866.901.1230
(T) 732.429.1000 • (F) 732.429.1001

* Darvon[®] is a registered trademark of Xanodyne